PK of Tofacitinib MR vs IR in Chinese Healthy Subjects

Phase 1, randomised, open-label trial of tofacitinib oral solution in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC) and 2 more (2 arms), sponsored by Pfizer. Primary endpoints: Area under the plasma concentration time profile from time zero extrapolated to infinite time at Day 1, Area under the plasma concentration time profile from time zero to the time of the last quantifiable concentration at Day 1 and 1 more. Started Dec 2018; status: completed.